Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOIMMUN
2025-520884-42-00Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jan 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tacrolimus in kidney allograft rejection (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Composite efficacy endpoint at 24 months. Planned start Jan 2025; status: authorised.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2025-520884-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520884-42-00.